title: In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation.
abstract: Ag presentation via HLA class II molecules in B lymphocytes depends on the coordinated action of HLA-DM, the catalyst of class II-peptide loading, and HLA-DO, a pH-dependent modulator of DM, the expression of which is almost completely restricted to B lymphocytes. The relative expression levels of both class II modulators are critical for the composition of the HLA class II peptide repertoire. The data in this work demonstrate that DO and DM expression are both dependent on the cellular activation status in primary human B lymphocytes. In vivo low-density activated primary human B lymphocytes show a prominent reduction in DO and DM expression when compared with high-density resting primary B lymphocytes. In vitro, reduction of DO and DM expression can be induced by B lymphocyte activation via the B cell receptor or by use of the phorbol ester, PMA. Specific inhibition of protein kinase C resulted in a significant reduction of HLA-DO and is potentially due to protein degradation in lysosomal compartments as the phenomenon is reversed by chloroquine. Thus, the expression of the dedicated HLA class II chaperone DM and its pH-dependent modulator DO is regulated and tightly controlled by the activation status of the B lymphocyte.
authors.affiliation: Groupe de Recherche sur les Lymphomes, Institut Albert Bonniot, Domaine de la Merci, La Tronche, France. Corinne.Roucard@ujf-grenoble.fr
authors.forename: C
authors.initials: C
authors.lastname: Roucard
authors.forename: C
authors.initials: C
authors.lastname: Thomas
authors.forename: M A
authors.initials: MA
authors.lastname: Pasquier
authors.forename: J
authors.initials: J
authors.lastname: Trowsdale
authors.forename: J J
authors.initials: JJ
authors.lastname: Sotto
authors.forename: J
authors.initials: J
authors.lastname: Neefjes
authors.forename: M
authors.initials: M
authors.lastname: van Ham
mesh_terms: D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis / Q000378:metabolism; D001402:B-Lymphocytes / Q000276:immunology*; D015153:Blotting, Western; D002478:Cells, Cultured; D002738:Chloroquine / Q000494:pharmacology; D015536:Down-Regulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006681:HLA-D Antigens / Q000378:metabolism*; D006684:HLA-DR Antigens / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D007211:Indoles / Q000494:pharmacology; D008213:Lymphocyte Activation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: D000944:Antigens, Differentiation, B-Lymphocyte; D004791:Enzyme Inhibitors; D006681:HLA-D Antigens; C084245:HLA-DM antigens; C046148:HLA-DO antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D007211:Indoles; C045084:invariant chain; D002738:Chloroquine; D011493:Protein Kinase C; C064758:Ro 31-8220